The original 2022 study demonstrated the p62-mediated AUTOTAC platform. A 2026 investigator conference abstract still describes IND-enabling preclinical work in neurodegenerative disease.
South KoreaFull profile →
Company database
Profiles, sources, and comparisons are open. Choose a field on the left to see its companies.
Search & refine Filters update automatically
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
5 matching companiesShowing 1–5 / 5
The website describes ORICISION as discovering both protein degraders and conformational correctors, emphasizing patient-derived models and clearance of disease-associated proteins.
United StatesFull profile →
The current website focuses on covalent chemistry and ALS / Parkinson's programs. An original 2021 announcement records a four-target Novartis collaboration.
United KingdomFull profile →
A 2026-06-23 announcement states that TRIM21 E3-associated TRIMTAC/TRIMGLUE selectively degrade toxic aggregates and oligomers while sparing functional monomers, in early portfolio development.
United KingdomFull profile →
Dyne describes its FORCE platform as a transferrin-receptor-binding Fab, linker, and therapeutic payload for muscle and CNS delivery. Oligonucleotide conjugation and candidate-specific clinical results should be assessed separately.
Coverage expands from sourced records; this database does not claim all biopharma companies.